The Synthetic Amorphous Silica and Silicate Industry Association recently published a press release that clarifies the difference between Crystalline Silica and Synthetic Amorphous Silica.
Third party auditing and certification of excipient suppliers can assist in the development, manufacture and supply of safe and effective medicinal products.
On July 15, 2015, FDA held a public meeting to seek input on the reauthorization of the Prescription Drug User Fee Act (2002) (PDUFA). David R. Schoneker presented comments during the meeting.
